HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Avon’s FY 2016 Marked By ‘Success Stories,’ But Not Enough Of Them

This article was originally published in The Rose Sheet

Executive Summary

Following steady improvements over the first three quarters of fiscal 2016, Avon ends the year on a sour note with a disappointing fourth quarter. However, the international direct seller exceeded its cost savings targets and is now embarking on the next phase of its transformation plan with greater focus on growth.

You may also be interested in...



Avon's Ongoing Struggles Prompt Renewed Investor Call For CEO Ouster

Management projects a strong second half after Avon's first-quarter sales advanced 2%, reported, but dipped in constant currency. Analysts received the guidance guardedly, and a group of investors led by Barington Capital are unconvinced the firm can turn things around under current leadership.

Avon Outlines Transformation, Cost-Savings Plan; Analysts Still Wary

Following Avon Products Inc.'s announcement last month that it will spin off its North American business, execs provide a strategy update for investors, including a $350m cost-savings plan.

Unilever’s Dove Recommits To ‘Real Women’ Against Rising AI Threat

Unilever PLC’s Dove and Baby Dove brands continue tackling prominent social causes with a vow to be responsible about representing women realistically in advertising in the age of AI and a renewed commitment to closing the Black maternal care gap.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS109099

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel